Michal Ayalon is the founder of Kamada. Backed by First Israel Mezzanine Investors, FIMI Opportunity Funds, The Phoenix Holdings Ltd..
Michal Ayalon, Ph.D. is a senior biopharmaceutical executive who currently serves as the Vice President of Research and Development at Kamada. Kamada is a plasma-derived protein therapeutics company. The company focuses on developing, manufacturing, and commercializing plasma-derived protein therapeutics.
Full founder directory · Investor directory · Company funding database · Fundraising library